pneumonia
defi
ned
infect
infl
ammat
lower
respiratori
tract
associ
parenchym
radiograph
opac
defi
nition
exclud
bronchiol
tracheiti
neonat
pneumonia
noninfecti
caus
pneumonia
pneumon
discuss
chapter
pediatr
intens
care
unit
picu
sever
pneumonia
type
may
encount
first
previous
healthi
child
may
admit
picu
sever
communityacquir
pneumonia
cap
pneumonia
usual
caus
organ
preval
outofhospit
environ
second
patient
genet
acquir
immun
defi
cienci
commonli
develop
sever
pneumonia
opportunist
infect
usual
infect
healthi
children
immunocompromis
patient
commonli
given
chemoradiotherapi
cancer
receiv
immunesuppress
agent
prevent
reject
episod
follow
solid
organ
hematopoiet
stem
cell
transplant
third
previous
healthi
immunocompromis
patient
may
acquir
nosocomi
pneumonia
hospit
stay
mechan
ventil
patient
especi
high
risk
develop
nosocomi
ventilatorassoci
pneumonia
vap
final
aspir
pneumonia
caus
chronic
inocul
lower
respiratori
tract
larg
amount
less
virul
bacteria
suscept
host
prone
aspir
also
observ
picu
classifi
cation
pneumonia
type
picu
import
major
implic
caus
microbi
agent
thu
choic
initi
empir
treatment
may
life
save
chapter
review
respiratori
host
defens
maintain
steril
lower
respiratori
tract
addit
pathogenesi
classifi
cation
treatment
option
pneumonia
empyema
picu
patient
briefl
discuss
potent
expiratori
maneuv
fundament
import
prevent
materi
aspir
lung
conduct
airway
also
contain
sever
antimicrobi
substanc
includ
immunoglobulin
igg
secretori
iga
complement
bind
enhanc
elimin
microbi
agent
addit
airway
epitheli
alveolar
type
ii
cell
secret
sever
antimicrobi
peptid
one
best
character
famili
antimicrobi
peptid
defensin
cysteinerich
peptid
possess
broad
antimicrobi
activ
import
recent
discoveri
expand
role
respiratori
airway
epithelium
innat
immun
defens
mechan
mimic
note
phagocyt
cell
respiratori
epitheli
cell
includ
atii
cell
express
tlr
capabl
express
varieti
cytokin
amplifi
infl
ammat
import
innat
immun
epitheli
cell
confi
rmed
mice
specifi
c
inhibit
nuclear
factor
nf
activ
restrict
distal
airway
epitheli
cell
mice
lack
abil
activ
epitheli
cell
exhibit
impair
infl
ammatori
respons
inhal
lp
data
provid
evid
distal
airway
epitheli
cell
signal
transduc
play
key
physiolog
role
lung
infl
ammat
vivo
alveolar
type
ii
cell
also
secret
surfact
protein
sp
spa
spd
collagenlik
lectin
collectin
agglutin
andor
opson
pathogen
enhanc
phagocytosi
innat
immun
cell
alveolar
macrophag
neutrophil
surfact
protein
may
addit
immunoregulatori
function
also
may
exhibit
direct
bactericid
effect
induc
damag
bacteri
cell
membran
function
spa
spd
host
defens
list
tabl
distal
airspac
alveolar
macrophag
fi
rst
phagocyt
cell
type
encount
pathogen
enter
lung
macrophag
capac
induc
gener
larg
amount
cytokin
chemokin
matrix
metalloproteinas
mmp
nitric
oxid
potent
oxid
particip
antimicrobi
defens
contrast
interstiti
macrophag
locat
lung
connect
tissu
serv
phagocyt
cell
antigenprocess
cell
tumor
necrosi
factor
tnf
macrophagederiv
multifunct
cytokin
express
earli
patient
anim
model
pneumonia
microb
also
induc
macrophag
gener
potent
chemokin
attract
circul
neutrophil
monocyt
lung
cytokin
chemokin
amplifi
infl
ammatori
respons
orchestr
polar
transit
innat
adapt
immun
function
elimin
invad
microorgan
figur
summar
cellular
secretori
peptid
compon
host
defens
microb
lower
respiratori
tract
disord
associ
impair
mechan
innat
adapt
host
respons
may
lead
develop
pneumonia
suscept
host
list
tabl
upper
respiratori
tract
normal
colon
nonpathogen
bacteri
fl
ora
physic
immunolog
host
defens
gener
ensur
bacteria
gain
access
lower
respiratori
tract
clear
pneumonia
occur
impair
host
defens
discuss
earlier
invas
virul
organ
invas
overwhelm
inoculum
less
virul
organ
fi
main
mode
pathogen
entri
lower
respiratori
tract
inhal
infecti
particl
probabl
import
pathogen
mechan
develop
cap
particular
import
pneumonia
caus
legionella
speci
mycobacterium
tuberculosi
contact
contamin
fomit
also
may
import
acquisit
viral
agent
especi
respiratori
syncyti
viru
viral
agent
caus
pneumonia
prolifer
spread
contigu
involv
lower
distal
portion
respiratori
tract
inhal
also
common
caus
pneumonia
caus
contamin
ventil
tube
endosom
figur
tolllik
receptor
tlr
ligand
lp
lipopolysaccharid
hsp
heat
shock
protein
addit
inhal
pneumonia
aris
follow
aspir
microorgan
oral
caviti
nasopharynx
invas
diseas
commonli
occur
upon
acquisit
new
serotyp
organ
patient
previou
experi
episod
vap
thought
develop
aspir
oropharyng
secret
contain
potenti
pathogen
organ
aspir
gastric
secret
may
also
contribut
although
like
lesser
degre
tracheal
intub
interrupt
bodi
anatom
physiolog
defens
aspir
make
mechan
ventil
major
risk
factor
vap
term
aspir
pneumonia
reserv
pneumonia
pneumon
result
aspir
larg
amount
gastric
oropharyng
content
may
contain
larg
inoculum
rel
nonvirul
bacteria
pathogen
commonli
produc
cap
vap
streptococcu
pneumonia
gramneg
bacilli
staphylococcu
aureu
rel
virul
bacteria
small
inoculum
requir
aspir
usual
subtl
immunocompromis
individu
addit
mode
pneumonia
acquisit
bacteremia
sepsi
hematogen
deposit
bacteria
respons
case
pneumonia
caus
staph
aureu
pseudomona
aeruginosa
escherichia
coli
reactiv
pathogen
take
place
set
defi
cit
cellmedi
immun
pathogen
pneumocysti
cariniijiroveci
tuberculosi
cytomegaloviru
cmv
may
remain
latent
mani
year
exposur
fl
are
activ
diseas
face
immun
compromis
reactiv
tuberculosi
occasion
occur
immunocompet
host
direct
inocul
rare
occur
result
surgeri
bronchoscopi
may
play
role
develop
pneumonia
patient
support
mechan
ventil
direct
extens
infect
lung
contigu
area
pleural
subdiaphragmat
space
rare
communityacquir
pneumonia
communityacquir
pneumonia
refer
pneumonia
previous
healthi
person
acquir
infect
outsid
hospit
one
common
seriou
infect
children
incid
case
per
children
industri
world
subset
patient
requir
picu
admiss
admiss
intens
care
unit
consid
patient
persist
hypoxemia
despit
oxygen
therapi
recurr
apnea
sign
respiratori
fatigu
without
mental
statu
chang
evid
compens
decompens
shock
infant
less
month
age
children
comorbid
condit
bronchopulmonari
dysplasia
cystic
fi
brosi
neuromuscular
disord
congenit
heart
diseas
immunodefi
cienci
disord
limit
respiratori
reserv
therefor
increas
risk
respiratori
failur
pneumonia
episod
adult
popul
american
british
thorac
societi
develop
guidelin
hospit
icu
admiss
patient
sever
cap
accord
american
thorac
societi
guidelin
admiss
icu
need
patient
sever
cap
defi
ned
presenc
either
one
two
major
criteria
presenc
two
three
minor
criteria
major
criteria
includ
need
mechan
ventil
septic
shock
minor
criteria
includ
systol
blood
pressur
mm
hg
multilobar
diseas
pao
fio
ratio
addit
pneumonia
sever
index
psi
score
identifi
es
adult
increas
risk
medic
complic
death
howev
similar
guidelin
score
grade
sever
pneumonia
children
develop
children
admit
picu
cap
commonli
infect
bacteri
viral
pathogen
streptococcu
pneumonia
commonli
identifi
ed
bacteri
caus
cap
infant
children
older
month
pneumonia
caus
group
streptococcu
staph
aureu
less
frequent
haemophilu
infl
uenza
pneumonia
becom
uncommon
follow
widespread
use
haemophilu
infl
uenza
type
b
immun
virus
identifi
ed
often
children
year
age
respiratori
syncyti
viru
common
viral
etiolog
infanc
adenoviru
infl
uenza
viru
parainfl
uenza
viru
recent
describ
human
metapneumonoviru
also
infrequ
detect
mycoplasma
pneumonia
chlamydia
pneumonia
common
older
children
adolesc
may
outbreak
acut
febril
ill
associ
respiratori
failur
shock
high
mortal
identifi
ed
investig
center
diseas
control
prevent
cdc
caus
hantaviru
unit
state
case
occur
west
mississippi
environment
exposur
infect
deer
mous
saliva
urin
fece
addit
novel
coronaviru
identifi
ed
caus
agent
sever
acut
respiratori
syndrom
sar
new
respiratori
ill
affect
adult
children
although
sever
diseas
less
children
adult
anoth
caus
sever
pneumonia
consid
tuberculosi
histori
contact
person
pulmonari
tuberculosi
usual
elicit
final
uncommon
caus
cap
otherwis
healthi
children
fungal
infect
includ
coccidiod
immiti
histoplasma
capsulatum
blastomyc
dermatitidi
organ
includ
differenti
diagnosi
caus
pneumonia
histori
resid
travel
area
endem
infect
occasion
infect
strep
pneumonia
mycoplasma
pneumonia
caus
necrot
pneumonia
secondari
invas
organ
exagger
host
immun
respons
compar
patient
pneumonia
parapneumon
effus
children
develop
necrot
pneumonia
exhibit
protract
hospit
cours
associ
higher
rate
complic
includ
bronchopleur
fi
stula
need
thoracotomi
fi
stula
repair
lobectomi
none
necrot
pneumonia
patient
immun
defi
cient
diagnosi
cap
usual
made
base
presenc
respiratori
symptom
cough
retract
febril
tachypn
child
presenc
infi
ltrate
chest
radiograph
confi
rm
diagnosi
pneumonia
infi
ltrate
gener
either
interstiti
alveolar
although
alveolar
infi
ltrate
commonli
observ
bacteri
pneumonia
studi
pattern
infi
ltrate
shown
correctli
differenti
viral
bacteri
pneumonia
chest
radiograph
also
detect
presenc
pleural
effus
pneumatocel
observ
staphylococc
pneumonia
presenc
airfl
uid
level
indic
abscess
format
initi
stabil
diagnost
test
perform
rapidli
avoid
delay
administr
initi
empir
therapi
addit
chest
radiograph
admit
patient
complet
blood
count
differenti
routin
blood
chemistri
test
includ
glucos
serum
sodium
liver
renal
function
test
electrolyt
admit
patient
oxygen
satur
assess
puls
oximetri
supplement
oxygen
administ
need
arteri
blood
ga
measur
patient
sever
ill
assess
level
oxygen
degre
carbon
dioxid
retent
critic
ill
patient
pneumonia
aggress
approach
determin
caus
microbi
agent
warrant
microbiolog
confi
rmation
ultim
obtain
approxim
children
cap
pleural
effus
present
aspir
pleural
fl
uid
gram
stain
cultur
prior
start
antibiot
valuabl
blood
cultur
may
reveal
organ
patient
bacteri
pneumonia
sputum
collect
usual
practic
infant
children
bacteri
organ
recov
nasopharynx
accur
predict
etiolog
pneumonia
howev
recoveri
virus
atyp
pathogen
nasopharynx
predict
bacteri
organ
recov
tracheal
secret
obtain
endotrach
tube
may
may
refl
ect
caus
agent
respons
lower
respiratori
tract
infect
specimen
consid
appropri
examin
contain
epitheli
cell
polymorphonuclear
leukocyt
low
power
primari
purpos
tracheal
aspir
sampl
visual
bacteri
morpholog
organ
anticip
appropri
drug
ad
initi
antibiot
regimen
eg
staph
aureu
enter
gramneg
antibiot
bronchoalveolar
lavag
bal
shown
rapid
rel
safe
rel
noninvas
diagnost
procedur
obtain
lower
respiratori
tract
sampl
microbi
identifi
cation
analysi
techniqu
use
identifi
pathogen
includ
antigen
detect
bacteria
virus
use
immunofl
uoresc
polymeras
chain
reaction
serolog
cold
agglutin
test
pneumonia
specifi
citi
cold
agglutin
test
pneumonia
almost
absolut
although
sensit
detect
mycoplasma
igm
enzymelink
immunoabsorb
assay
elisa
sensit
techniqu
consid
children
immunocompromis
patient
whose
immun
mechan
defi
cient
congenit
immun
defi
cienci
syndrom
acquir
immunolog
disord
exposur
cytotox
chemotherapi
steroid
addit
recipi
solid
organ
hematopoiet
stem
cell
transplant
hsct
frequent
given
lifelong
treatment
immunosuppress
agent
design
prevent
graft
reject
graftversushost
diseas
patient
develop
sever
neutropenia
ie
absolut
neutrophil
count
cellsml
lymphopenia
prolong
period
time
greatest
risk
develop
varieti
infecti
complic
includ
lifethreaten
pneumonia
lung
predomin
site
opportunist
infect
immunocompromis
patient
immunosuppress
patient
predispos
develop
infect
ubiquit
microorgan
normal
caus
diseas
healthi
peopl
also
suscept
usual
caus
pneumonia
affect
anyon
sequenc
differ
organ
appear
immunosuppress
posttranspl
recipi
fairli
characterist
nosocomi
bacteri
infect
remain
common
caus
pneumonia
earli
posttranspl
neutropen
phase
staphylococcu
aureu
gramneg
pathogen
predomin
addit
fungal
infect
candida
aspergillu
speci
uncommonli
seen
sever
neutropen
phase
second
period
month
solid
organ
transplant
time
opportunist
infect
commonli
associ
transplant
includ
nocardia
p
cariniijiroveci
cmv
observ
third
period
month
patient
categor
differ
risk
group
depend
level
function
allograft
degre
immunosuppress
receiv
minim
immunosuppress
therapi
subject
mainli
pathogen
rest
commun
allograft
dysfunct
ongo
heavi
immunosuppress
therapi
remain
subject
opportunist
infect
seen
second
period
lung
transplant
recipi
develop
bronchiol
obliteran
hsct
recipi
develop
graftversushost
diseas
remain
especi
risk
infect
pulmonari
infi
ltrate
immunocompromis
host
may
caus
varieti
organ
may
noninfecti
caus
progress
respiratori
failur
may
rapid
aggress
approach
diagnosi
treatment
necessari
limit
morbid
mortal
initi
broadspectrum
therapi
import
alter
empir
regimen
clinic
situat
stabil
diagnost
inform
obtain
immunocompromis
host
bal
procedur
perform
promptli
rule
infecti
etiolog
list
suggest
bal
fl
uid
analysi
studi
cultur
bronchoalveolar
lavag
help
diagnosi
p
cariniijiroveci
cmv
tuberculosi
fungal
infect
howev
abil
bal
fl
uid
analysi
cultur
detect
invas
aspergillosi
one
lethal
infecti
complic
transplant
limit
diagnost
yield
aspergillu
speci
infect
enhanc
recent
develop
elisa
detect
galactomannan
fungal
cell
wall
compon
releas
invas
diseas
histopatholog
analysi
cultur
open
lung
biopsi
specimen
may
provid
accur
determin
caus
pulmonari
infi
ltrate
pediatr
patient
howev
open
lung
biopsi
associ
signifi
cant
surgic
risk
critic
ill
patient
open
lung
biopsi
effect
least
riski
perform
earli
cours
patient
develop
nodular
infi
ltrate
requir
rapid
differenti
fungal
infect
benign
lesion
chemoprophylaxi
opportunist
infect
import
compon
manag
posttranspl
immunosuppress
patient
widespread
introduct
chemoprophylaxi
p
carinii
pneumonia
pcp
observ
common
opportunist
infect
among
transplant
recipi
administr
lowdos
trimethoprimsulfamethoxazol
altern
prophylact
agent
pentamidin
pcp
effect
prevent
prophylaxi
also
recommend
cmv
highrisk
cmv
seroneg
recipi
prophylaxi
includ
intraven
ganciclovir
day
follow
oral
ganciclovir
capsul
three
month
aspir
pneumonia
refer
pulmonari
consequ
result
abnorm
entri
fl
uid
formula
endogen
secret
lower
airway
usual
compromis
host
defens
protect
lower
airway
includ
glottic
closur
cough
refl
ex
clear
mechan
histori
seizur
anesthesia
episod
reduc
level
conscious
neurolog
diseas
dysphagia
gastroesophag
refl
ux
risk
factor
aspir
risk
aspir
especi
high
remov
endotrach
tube
residu
effect
sed
drug
presenc
nasogastr
tube
swallow
dysfunct
relat
alter
upperairway
sensit
glottic
injuri
laryng
muscular
dysfunct
aspir
pneumonia
may
classifi
ed
three
clinic
syndrom
chemic
pneumon
bacteri
infect
airway
obstruct
anim
model
develop
chemic
pneumon
requir
mlkg
inoculum
fl
uid
ph
initi
infl
ammatori
reaction
may
lead
pulmonari
fi
brosi
bacteria
present
aspir
oropharyng
gastric
secret
may
also
lead
pneumonia
aspir
pneumonia
may
involv
particul
matter
foreign
bodi
addit
caus
airway
obstruct
refl
ux
airway
closur
may
synergist
contribut
acidinduc
lung
injuri
true
aspir
pneumonia
convent
usual
refer
infect
caus
less
virul
bacteria
primarili
anaerob
common
constitu
normal
fl
ora
suscept
host
prone
aspir
pneumonia
commonli
caus
oropharyng
fl
ora
includ
anaerob
gramneg
bacilli
bacteroid
fragili
fusobacterium
nucleatum
peptostreptococcu
prevotella
anaerob
gramposit
bacilli
clostridium
eubacterium
actinomyc
lactobacillu
propionibacterium
aspir
usual
occur
patient
supin
immedi
feed
supin
posit
right
upper
lobe
depend
part
lung
frequent
affect
commonli
impair
airway
protect
respons
observ
presenc
tracheoesophag
malform
investig
recurr
aspir
note
otherwis
healthi
infant
clinic
present
cours
chemic
pneumon
inhal
gastric
content
rang
mild
selflimit
sever
life
threaten
depend
natur
aspir
underli
condit
host
absenc
wit
inhal
vomit
diagnosi
diffi
cult
requir
high
index
suspicion
patient
risk
factor
aspir
absenc
obviou
predisposit
abrupt
onset
selflimit
ill
character
dyspnea
cyanosi
lowgrad
fever
associ
diffus
rale
hypoxemia
alveolar
infi
ltrate
depend
lobe
suggest
aspir
bal
perform
assess
lipidladen
macrophag
index
use
oilredo
stain
help
confi
rming
diagnosi
presenc
foulsmel
putrid
discharg
sputum
pleural
fl
uid
regard
diagnost
anaerob
infect
patient
often
prolong
fever
product
cough
frequent
show
blood
sputum
indic
necrosi
tissu
death
lung
aspir
persist
fi
brosi
bronchiectasi
may
result
number
intervent
eg
posit
dietari
chang
drug
oral
hygien
tube
feed
propos
prevent
aspir
patient
observ
aspir
immedi
tracheal
suction
bronchoscopi
clear
fl
uid
particul
matter
may
caus
obstruct
use
corticosteroid
treatment
chemic
pneumon
controversi
antibiot
use
earli
cours
unless
superimpos
bacteri
infect
suspect
nation
nosocomi
infect
surveil
nni
program
sponsor
cdc
defi
ne
vap
pneumonia
patient
mechan
ventil
hr
develop
new
persist
radiograph
evid
focal
infi
ltrate
addit
patient
two
follow
temperatur
leukocytosi
white
blood
cell
purul
sputum
white
blood
cellshighpow
fi
eld
tracheal
aspir
gram
stain
blood
stream
infect
vap
second
common
caus
nosocomi
infect
picu
mean
vap
rate
children
rang
ventil
day
account
hospitalacquir
infect
infect
acquir
picu
associ
signifi
cantli
increas
risk
death
nosocomi
pneumonia
vap
typic
categor
either
earli
onset
occur
fi
rst
day
mechan
ventil
late
onset
distinct
import
microbiolog
earlyonset
nosocomi
pneumonia
vap
commonli
caus
antibioticsensit
communityacquir
organ
eg
strep
pneumonia
staph
aureu
lateonset
nosocomi
pneumonia
vap
commonli
caus
antibioticresist
nosocomi
organ
eg
p
aeruginosa
methicillinresist
staph
aureu
acinetobact
speci
enterobact
speci
winter
respiratori
viral
season
patient
medic
care
environ
risk
diseas
due
respiratori
syncyti
viru
parainfl
uenza
infl
uenza
virus
legionnair
diseas
multisystem
ill
pneumonia
caus
legionella
speci
usual
present
contamin
water
legionnair
diseas
less
common
children
adult
compar
postmortem
lung
biopsi
cultur
result
use
clinic
criteria
diagnos
vap
lung
infi
ltrate
leukocytosi
purul
secret
fever
sensit
specifi
citi
clearli
number
noninfecti
caus
fever
pulmonari
infi
ltrate
also
occur
patient
make
clinic
criteria
nonspecifi
c
diagnosi
vap
lung
infi
ltrate
may
caus
pulmonari
hemorrhag
chemic
aspir
atelectasi
fever
may
caus
drug
reaction
extrapulmonari
infect
blood
transfus
autopsi
result
seri
patient
acut
lung
injuri
demonstr
clinic
criteria
alon
led
incorrect
diagnosi
vap
clinic
suspect
case
limit
encourag
use
invas
approach
sampl
cultur
materi
lower
respiratori
tract
accur
diagnosi
vap
ventilatorassoci
pneumonia
accur
diagnos
quantit
cultur
microscop
examin
lower
respiratori
tract
secret
best
obtain
bronchoscopi
bal
cultur
tracheal
aspir
use
establish
caus
vap
although
cultur
highli
sensit
specifi
citi
low
even
cultur
quantit
combin
clinic
bacteriolog
evalu
probabl
best
way
achiev
object
correctli
diagnos
vap
appropri
use
antimicrobi
agent
main
aim
diagnost
approach
rapidli
identifi
patient
true
lung
bacteri
infect
select
appropri
initi
antimicrobi
therapi
adjust
therapi
base
antibiot
sensit
withhold
antibiot
patient
without
vap
guidelin
prevent
vap
children
lack
data
extrapol
adult
studi
support
routin
elev
head
bed
appropri
use
sed
muscl
relax
adequ
oral
circuit
hygien
empyema
presenc
purul
materi
contain
polymorphonuclear
leukocyt
fi
brin
pleural
caviti
empyema
usual
complic
inadequ
treat
bacteri
cap
although
may
occur
trauma
thorac
surgeri
intrathorac
esophag
perfor
although
parapneumon
pleural
effus
note
children
pneumonia
empyema
rare
present
case
format
empyema
divid
three
stage
exud
fi
brinopurul
organ
exud
stage
pu
accumul
follow
fi
brin
deposit
locul
pleural
fl
uid
known
fi
brinopurul
stage
organ
stage
character
fi
broblast
prolifer
time
potenti
lung
entrap
scar
typic
pleural
fl
uid
empyema
exud
caus
protein
leakag
capillari
increas
permeabl
increas
hydrostat
pressur
infl
ammatori
process
although
distinct
transud
exud
sometim
diffi
cult
make
sever
featur
favor
exud
process
least
one
follow
three
criteria
present
fl
uid
virtual
alway
exud
pleural
fl
uid
protein
gdl
proteinserum
protein
ratio
greater
pleural
fl
uid
lactat
dehydrogenas
ldh
serum
ldh
ratio
greater
andor
pleural
fl
uid
ldh
greater
two
third
serum
ldh
common
organ
caus
empyema
children
strep
pneumonia
staph
aureu
group
streptococci
haemophilu
infl
uenza
rare
encount
sinc
advent
h
infl
uenza
b
vaccin
mycoplasma
pneumonia
virus
rare
result
exud
pleural
effus
seri
pediatr
patient
empyema
secondari
anaerob
infect
data
highlight
import
anaerob
bacteria
select
case
empyema
children
adolesc
addit
tuberculosi
alway
consid
differenti
diagnosi
purifi
ed
protein
deriv
test
perform
differenti
diagnosi
patient
pleural
effus
shown
tabl
presenc
fever
associ
clinic
sign
bacteri
pneumonia
clue
underli
pneumonia
caus
effus
later
decubitu
radiograph
ultrasonographi
comput
tomographi
may
differenti
whether
fl
uid
locul
sampl
fl
uid
obtain
thoracentesi
order
determin
effus
transud
versu
exud
pleural
cultur
posit
approxim
one
half
pediatr
patient
empyema
blood
cultur
urin
latex
agglutin
may
help
identifi
bacteri
pathogen
pneumatocel
pneumothorax
seen
chest
fi
lm
suggest
staph
aureu
caus
empyema
specifi
c
organ
identifi
ed
empir
antibiot
therapi
institut
might
includ
thirdgener
cephalosporin
antistaphylococc
penicillin
antibiot
adjust
organ
identifi
ed
antibiot
therapi
intraven
patient
becom
afebril
continu
oral
addit
week
major
debat
proper
adjuv
treatment
children
empyema
prospect
random
control
studi
children
empyema
lack
except
start
appropri
empir
antibiot
consensu
place
chest
tube
instil
fi
brinolyt
agent
take
oper
room
light
suggest
chest
tube
insert
pleural
fl
uid
gross
pu
gram
stain
pleural
fl
uid
posit
pleural
fl
uid
glucos
level
mgdl
pleural
fl
uid
ph
level
less
drainag
chest
tube
unsatisfactori
either
urokinas
tissu
plasminogen
activ
tpa
inject
intrapleur
drainag
still
unsatisfactori
decort
consid
stagerel
approach
manag
empyema
perhap
effi
caciou
costeffect
exud
stage
conserv
treatment
use
tube
drainag
may
suffi
ce
fibrinolyt
treatment
may
use
fi
brinopurul
stage
contrast
aggress
treatment
use
surgic
decort
may
necessari
organ
stage
advent
videoassist
thoracoscopi
vat
tradit
approach
manag
empyema
children
challeng
videoassist
techniqu
offer
distinct
advantag
accur
stage
diseas
process
effect
manag
organ
pleural
diseas
postop
patient
comfort
retrospect
studi
perform
earli
vat
hr
admiss
children
empyema
associ
signifi
cantli
decreas
length
hospit
stay
compar
perform
late
vat
hr
admiss
children
treat
empyema
gener
recov
residu
sequela
radiograph
time
discharg
usual
show
pleural
thicken
later
resolv
followup
pulmonari
function
test
physic
examin
also
usual
normal
consist
mild
restrict
diseas
epidemiolog
investig
clearli
demonstr
indiscrimin
administr
antibiot
agent
patient
picu
contribut
emerg
multiresist
pathogen
potenti
increas
morbid
mortal
preval
penicillinresist
strain
strep
pneumonia
methicillinresist
staph
aureu
vancomycinresist
enterococcu
gramneg
bacteria
produc
extendedspectrum
increas
despit
concern
clear
patient
surviv
may
improv
pneumonia
correctli
rapidli
treat
adult
inappropri
initi
antibiot
therapi
strongli
associ
fatal
therefor
may
conclud
empir
antibiot
treatment
sever
pneumonia
indic
choic
antibiot
base
sever
factor
includ
age
patient
type
pneumonia
local
resist
pattern
predomin
bacteri
pathogen
suggest
choic
initi
empir
antibiot
coverag
pneumonia
picu
list
tabl
aspir
pneumonia
occur
commun
treat
ampicillinsulbactam
empir
treatment
pneumonia
immunocompromis
host
requir
broadspectrum
gramposit
gramneg
coverag
immunocompromis
patient
especi
suscept
varieti
lifethreaten
opportunist
viral
fungal
pneumonia
requir
prompt
diagnosi
aggress
treatment
exampl
trimethoprimsulfamethoxazol
pentamidin
given
p
cariniijiroveci
amphotericin
b
caspofungin
candida
aspergillu
speci
acyclovir
herp
amantadin
infl
uenza
ganciclovir
foscarnet
cmv
ribavirin
sever
respiratori
syncyti
viru
empir
regimen
may
need
modifi
ed
result
cultur
antibiot
suscept
test
avail
infl
ammatori
respons
infect
necessari
host
defens
contribut
system
toxic
lung
injuri
may
result
pneumonia
set
adjunct
treatment
lower
respiratori
infect
antiinfl
ammatori
agent
reduc
morbid
corticosteroid
welldocu
role
manag
p
cariniijiroveci
pneumonia
multicent
trial
infus
hydrocortison
signifi
cantli
decreas
length
hospit
stay
prevent
mortal
adult
patient
cap
corticosteroid
also
may
effect
circumst
treatment
infl
ammatori
sequela
respiratori
tract
infect
tubercul
pleurisi
bronchiol
obliteran
organ
pneumonia
boop
strategi
target
specifi
c
cytokin
effect
date
remain
activ
area
investig
enhanc
understand
interact
pathogen
compon
tlr
may
help
one
day
control
contain
infecti
diseas
immun
reduc
incid
sever
seriou
childhood
diseas
immun
infl
uenza
increasingli
resist
pneumococci
play
critic
role
prevent
pneumonia
particularli
immunocompromis
patient
